The Technology, Exercise Programming, and Activity Prescription for Enhanced Mobility (TEAM) Study (TEAM)

June 10, 2024 updated by: Western University, Canada

Novel Uses of Technology for Individuals With Mild to Moderate Hip or Knee Osteoarthritis: The Technology, Exercise Programming, and Activity Prescription for Enhanced Mobility (TEAM) Study

Many individuals with osteoarthritis (OA) (up to 45%) are referred to an orthopaedic surgeon for a joint replacement prematurely or will not be candidates for surgery. These individuals need appropriate (non-operative) care to help reduce their pain and enhance their mobility. We are studying the use of innovative technology to help physicians give physical activity advice for patients to become more active and provide free online resources to help patients understand OA self-management and exercise, especially when they have barriers to accessing formal care. Individuals with OA that are referred to a specialized clinic will receive one of three interventions: usual care (handout on resources), a physical activity prescription by a doctor, or the prescription and a link to a free web-based platform (website) on non-operative management of OA with patient education and exercise videos. Our goal is to help with non-operative management strategies to improve quality of life, reduce pain, improve mobility, and possibly delay or prevent a joint replacement.

Osteoarthritis is a condition where people feel joint pain or stiffness. Joints are the body parts where two bones join together with softer material (cartilage) between them. In osteoarthritis, this cartilage wears down. It is the biggest cause for disability worldwide. Helping people with osteoarthritis starts with education, physical activity, and physiotherapy. Doctors can also prescribe braces, injections or medications. For severe osteoarthritis when nothing else helps, surgery can be done to replace the joint.

Doctors often refer patients for surgery too soon. Skipping steps of care may mean unnecessary surgery and longer wait times. The Musculoskeletal Rapid Access Clinic (now called Clinic) in London was set up to solve these problems. They screen patients before referring them to a surgeon, and do not refer almost half of patients. Our goal is to support these patients with new ways to make their non-surgical treatment better.

The first way is through physical activity 'prescription'. It works well for other chronic conditions and patients say it helps. We don't know how well it works for people with osteoarthritis. Most doctors have little time, training or experience for prescribing physical activity. Technology can make it easier for doctors and patients. We have designed a tool to help doctors prescribe physical activity and a smartphone app to track patient activity. We have also created a free website. This includes patient education, exercise videos, and virtual physiotherapy. This can be important for individuals who can't access in-person care.

Study Overview

Status

Active, not recruiting

Intervention / Treatment

Detailed Description

Osteoarthritis (OA) is the leading cause of disability worldwide and affects more than 4.4 million Canadians. Current evidence-based guidelines for OA management recommend weight management, patient education, physical activity, physiotherapy (PT), bracing, viscosupplementation, and anti-inflammatory/pain medications prior to joint replacement surgery. Unfortunately, current practice trends are not consistent with these guidelines, as nearly half of patients with OA referred to orthopedic surgeons do not require total joint arthroplasty (TJA) at the time of initial consultation. Through the Southwest Musculoskeletal Rapid Access Clinic (RAC), approximately ten referrals (20%) are rejected each day due to OA criteria not met, and a further 20% are assessed as non-operative.

We aim to identify individuals with 'mild to moderate' OA and optimize their first-line non-operative management, starting with physical activity and education.

Physical activity prescriptions are effective in increasing patient levels of physical activity, and 93% of patients surveyed want advice on physical activity from their physicians; but it is underused.

Physicians cite lack of time and inadequate training as barriers. Electronic screening of physical activity behaviours can save time for physicians, and the use of digital health tools can improve physical activity levels.

Patient education and physiotherapist-led group exercise therapy programs have shown to delay progression of knee OA symptoms and improve pain and function; however, two of the most significant barriers to accessing exercise programming is the cost (~approximate $425-475 per 6-8-week session) and accessibility to attend the exercise session (proximity to facility, remote/rural communities, etc.).

The Need for a Solution that targets both Providers and Patients Screening for baseline physical activity levels and including educational components significantly increase intervention effectiveness.

We have previously tested the feasibility of implementing an e-health tool to support physical activity counselling by physicians during patients' periodic health review. We will adapt and implement this tool, Physical Activity and App Prescription (PARx) to screen and provide tailored resources for physical activity in the setting of OA. We will use tablet computers and email, directly linked with the electronic medical record (EMR), to engage patients in contemplating their own physical activity levels, start conversations with their healthcare providers (in this case, primary care physicians with additional training in sport and exercise medicine), and support customized, patient-centered health care. After patients enter their information, they will receive evidence-based behavioural change supports to help them meet their goals.

The automated algorithm assesses current activity level, risk factors/comorbidities and readiness for change. Based on the answers provided, patients are risk-stratified and tailored resources will be provided to the patient and to their clinician in the form of decision support tools embedded in the EMR. This will include the novel implementation of an exercise tracking platform via the smartphone app (myrecovery.ai).

The web-based platform Joint Management (JM) is a free, readily accessible evidenced-based resource focusing on non-operative management strategies for mild to moderate hip and knee OA. The platform will include exercise programming (videos, pictures, and descriptions of the exercises) and patient education (benefits of exercise, lifestyle modifications, nutrition, injections, etc.), to assist the patient engage in self-management. JM will also include the option for (paid) virtual access to PTs, who can provide individualized support, recommendations and exercise programming via the platform.

RATIONALE:

Creating customized physical activity plans with automated reminders and other supports addresses the problem of self-efficacy in providers by developing an evidence-based automated method, while also addressing the issue of patient adherence by using tailored behaviour change techniques, through assessing readiness for change, and helping patients create new habits.

The motivation for JM is to create a free, online evidence-based OA education and exercise programming resource for those that are not able to afford or access community-based exercise programs. The virtual PT option will help optimize patient's experience with the web-based platform, offering support and personalized recommendations regarding management of their condition and exercise programming tailored to their specific abilities, preferences, and needs.

Why this is Innovative:

The evidence for using patient-reported measures and functional outcomes to guide quality improvement for personalized OA care in a systematic manner is in an early stage, meaning that this project can not only impact healthcare delivery and translate new knowledge into medical practice but help position Western University as a leader in this area. The novel technologies (PARx and JM) are innovative tools informed by patient priorities and co-designed with our patient partners, specifically geared towards 1) developing new and more personalized treatment approaches, 2) developing more effective self-management tools, and 3) reducing disparities in vulnerable and hard-to-reach populations. To this end, we will share our findings broadly with our patient partners and reach out to these harder-to-reach groups in particular.

EXPECTED OUTCOMES:

Health Outcomes: We expect to increase patients' physical activity and improve outcomes for individuals with mild to moderate OA. We aim to optimize non-operative management of OA symptoms and therefore possibly delay and/or prevent the need for TJA.

Academic Outcomes: We expect to develop a model of physical activity prescription and patient education that can be scaled up for implementation in primary care.

Societal Outcomes: Both novel technologies have the potential to be implemented across Canada, targeting modifying disease progression and, ideally, delaying or preventing TJA.

Innovative Technology 1: Physical Activity (PA) and App Prescription (Rx) (PARx) Physical Activity and App Prescription (PARx): Tablet/email software (REDCap) is used to collect physical activity data from patient input and prompt intervention by providers. The automated algorithm assesses current activity level, risk factors/comorbidities and readiness for change. Based upon their answers, patients will be risk-stratified and tailored resources will be provided to them in the form of a personalized prescription and free smartphone app (myrecovery.ai) to track activity levels.

Innovative Technology 2: Joint Management (JM) Joint Management (JM): This is a free online evidence-based OA education and exercise programming resource for those that are not able to afford or access community-based exercise programs, with a virtual physiotherapy (PT) option to offer support and personalized recommendations.

OBJECTIVES:

The objective of the proposed study is to 1) determine if PARx and JM will improve pain, increase physical activity levels, and improve functional outcomes in patients with mild to moderate hip or knee OA

RESEARCH QUESTIONS:

  1. Does the use of novel technology (PARx) affect patient reported outcomes in individuals with mild to moderate hip or knee OA?
  2. Does PARx influence activity levels in individuals with mild to moderate hip or knee OA?
  3. Does the use of novel technology (PARx and JM) affect patient reported and functional outcomes in individuals with mild to moderate hip or knee OA?
  4. What are the experiences and perceptions of patients and physicians during this process?

SPECIFIC AIMS:

Measure and compare A1) patient reported outcomes (pain, joint stiffness, disability, quality of life, disease knowledge, self-efficacy, depression, and fatigue), A2) physical activity levels, and A3) functional outcomes with those that have access (PARx and JM) and those that do not have access (usual care) to the technology. Determine A4) participant and physician experiences.

HYPOTHESES:

We hypothesize that access to technology-facilitated physical activity prescription (PARx) and access to the web-based platform (JM) will H1) improve patient reported outcomes (pain, joint stiffness, disability, quality of life, disease knowledge, self-efficacy, depression, and fatigue), H2) increase PA levels, and H3) improve functional outcomes in individuals with mild to moderate hip or knee OA compared to usual care. We hypothesize that access to JM will result in a greater improvement than PARx alone.

Study Type

Interventional

Enrollment (Estimated)

192

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • London, Ontario, Canada, N6A 3K7
        • Fowler Kennedy Sports Medicine Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 74 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • 40-74 years of age
  • Screened by the Southwest Musculoskeletal RAC as "mild to moderate OA" using clinical and radiographic criteria

Exclusion Criteria:

  • Concomitant end-stage OA (awaiting/prior TJA)
  • Inflammatory arthritis (rheumatoid, psoriatic, or disease-modifying anti-rheumatic drug exposure)
  • Unstable medical conditions that would preclude physical activity prescription (e.g. unstable angina, uncontrolled Type 2 Diabetes)
  • Not able/willing to follow up for the study period
  • Does not have access to the internet
  • Cannot communicate in English.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Usual Care
Patients will receive the usual care.
Experimental: PAARx
Patients will be prescribed technology-based physical activity programming.
Prescription Physical Activity Programming Application
Experimental: PAARx and JM
Patients will be prescribed technology-based physical activity programming and be referred to a web-based resource for evidence-based joint management.
Prescription Physical Activity Programming Application
Joint Management (JM) web-based joint management resource.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
height
Time Frame: Baseline
height in cm
Baseline
height
Time Frame: 2 months
height in cm
2 months
height
Time Frame: 6 months
height in cm
6 months
height
Time Frame: 12 months
height in cm
12 months
body mass index (derived)
Time Frame: Baseline
body mass index as calculated with height and weight
Baseline
body mass index (derived)
Time Frame: 2 months
body mass index as calculated with height and weight
2 months
body mass index (derived)
Time Frame: 6 months
body mass index as calculated with height and weight
6 months
body mass index (derived)
Time Frame: 12 months
body mass index as calculated with height and weight
12 months
abdominal circumference
Time Frame: Baseline
abdominal circumference in cm
Baseline
abdominal circumference
Time Frame: 2 months
abdominal circumference in cm
2 months
abdominal circumference
Time Frame: 6 months
abdominal circumference in cm
6 months
abdominal circumference
Time Frame: 12 months
abdominal circumference in cm
12 months
weight
Time Frame: Baseline

weight kg

, weight, body mass index (derived), abdominal circumference, and medical history to assess for comorbid disease.

Baseline
weight
Time Frame: 2 months

weight kg

, weight, body mass index (derived), abdominal circumference, and medical history to assess for comorbid disease.

2 months
weight
Time Frame: 6 months

weight kg

, weight, body mass index (derived), abdominal circumference, and medical history to assess for comorbid disease.

6 months
weight
Time Frame: 12 months

weight kg

, weight, body mass index (derived), abdominal circumference, and medical history to assess for comorbid disease.

12 months
PA Evaluation
Time Frame: Baseline
PA levels will be measured as a composite measure using smartphone app/accelerometer data (myrecovery.ai; steps per day, light/moderate/vigorous activity, and total MET-min) via the International PA Questionnaire - Short Form (IPAQ-SF) [15].
Baseline
PA Evaluation
Time Frame: 2 months
PA levels will be measured as a composite measure using smartphone app/accelerometer data (myrecovery.ai; steps per day, light/moderate/vigorous activity, and total MET-min) via the International PA Questionnaire - Short Form (IPAQ-SF) [15].
2 months
PA Evaluation
Time Frame: 6 months
PA levels will be measured as a composite measure using smartphone app/accelerometer data (myrecovery.ai; steps per day, light/moderate/vigorous activity, and total MET-min) via the International PA Questionnaire - Short Form (IPAQ-SF) [15].
6 months
PA Evaluation
Time Frame: 12 months
PA levels will be measured as a composite measure using smartphone app/accelerometer data (myrecovery.ai; steps per day, light/moderate/vigorous activity, and total MET-min) via the International PA Questionnaire - Short Form (IPAQ-SF) [15].
12 months
Functional Assessment 30 second sit-to-stand test
Time Frame: Baseline
30 second sit-to-stand test
Baseline
Functional Assessment 30 second sit-to-stand test
Time Frame: 2 months
30 second sit-to-stand test
2 months
Functional Assessment 30 second sit-to-stand test
Time Frame: 6 months
30 second sit-to-stand test
6 months
Functional Assessment 30 second sit-to-stand test
Time Frame: 12 months
30 second sit-to-stand test
12 months
Functional Assessment 40-meter fast-paced walk test
Time Frame: Baseline
40-meter fast-paced walk test
Baseline
Functional Assessment 40-meter fast-paced walk test
Time Frame: 2 months
40-meter fast-paced walk test
2 months
Functional Assessment 40-meter fast-paced walk test
Time Frame: 6 months
40-meter fast-paced walk test
6 months
Functional Assessment 40-meter fast-paced walk test
Time Frame: 12 months
40-meter fast-paced walk test
12 months
Hip Disability and OA Outcome Score (HOOS)
Time Frame: Baseline
Hip Disability and Osteoarthritis Outcome Score (HOOS) assesses patient pain (10 items), satisfaction including stiffness and range of motion (5 items), activity limitations-daily living (17 items), sports and recreation function (4 items), and hip related quality of life (4 items). Scores range from 0 to 100 with a score of 0 indicating the worst possible hip symptoms and 100 indicating no hip symptoms. This is a patient reported joint-specific score, which may be useful for assessing changes in hip pathology over time, with or without treatment.
Baseline
Hip Disability and OA Outcome Score (HOOS)
Time Frame: 2 months
Hip Disability and Osteoarthritis Outcome Score (HOOS) assesses patient pain (10 items), satisfaction including stiffness and range of motion (5 items), activity limitations-daily living (17 items), sports and recreation function (4 items), and hip related quality of life (4 items). Scores range from 0 to 100 with a score of 0 indicating the worst possible hip symptoms and 100 indicating no hip symptoms. This is a patient reported joint-specific score, which may be useful for assessing changes in hip pathology over time, with or without treatment.
2 months
Hip Disability and OA Outcome Score (HOOS)
Time Frame: 6 months
Hip Disability and Osteoarthritis Outcome Score (HOOS) assesses patient pain (10 items), satisfaction including stiffness and range of motion (5 items), activity limitations-daily living (17 items), sports and recreation function (4 items), and hip related quality of life (4 items). Scores range from 0 to 100 with a score of 0 indicating the worst possible hip symptoms and 100 indicating no hip symptoms. This is a patient reported joint-specific score, which may be useful for assessing changes in hip pathology over time, with or without treatment.
6 months
Hip Disability and OA Outcome Score (HOOS)
Time Frame: 12 months
Hip Disability and Osteoarthritis Outcome Score (HOOS) assesses patient pain (10 items), satisfaction including stiffness and range of motion (5 items), activity limitations-daily living (17 items), sports and recreation function (4 items), and hip related quality of life (4 items). Scores range from 0 to 100 with a score of 0 indicating the worst possible hip symptoms and 100 indicating no hip symptoms. This is a patient reported joint-specific score, which may be useful for assessing changes in hip pathology over time, with or without treatment.
12 months
Knee OA Outcome Score (KOOS)
Time Frame: Baseline
Knee injury and Osteoarthritis Outcome Score (KOOS) assesses patient pain (9 items), other symptoms (7 items), function in daily living (17 items), function in sport and recreation (5 items), and knee related quality of life (4 items). Scores range from 0 to 100 with a score of 0 indicating the worst possible knee symptoms and 100 indicating no knee symptoms. The KOOS is a patient reported joint-specific score, which may be useful for assessing changes in knee pathology over time, with or without treatment.
Baseline
Knee OA Outcome Score (KOOS)
Time Frame: 2 months
Knee injury and Osteoarthritis Outcome Score (KOOS) assesses patient pain (9 items), other symptoms (7 items), function in daily living (17 items), function in sport and recreation (5 items), and knee related quality of life (4 items). Scores range from 0 to 100 with a score of 0 indicating the worst possible knee symptoms and 100 indicating no knee symptoms. The KOOS is a patient reported joint-specific score, which may be useful for assessing changes in knee pathology over time, with or without treatment.
2 months
Knee OA Outcome Score (KOOS)
Time Frame: 6 months
Knee injury and Osteoarthritis Outcome Score (KOOS) assesses patient pain (9 items), other symptoms (7 items), function in daily living (17 items), function in sport and recreation (5 items), and knee related quality of life (4 items). Scores range from 0 to 100 with a score of 0 indicating the worst possible knee symptoms and 100 indicating no knee symptoms. The KOOS is a patient reported joint-specific score, which may be useful for assessing changes in knee pathology over time, with or without treatment.
6 months
Knee OA Outcome Score (KOOS)
Time Frame: 12 months
Knee injury and Osteoarthritis Outcome Score (KOOS) assesses patient pain (9 items), other symptoms (7 items), function in daily living (17 items), function in sport and recreation (5 items), and knee related quality of life (4 items). Scores range from 0 to 100 with a score of 0 indicating the worst possible knee symptoms and 100 indicating no knee symptoms. The KOOS is a patient reported joint-specific score, which may be useful for assessing changes in knee pathology over time, with or without treatment.
12 months
Intermittent and Constant OA Pain (ICOAP)
Time Frame: Baseline
This 11-item tool is designed to assess pain in individuals with hip or knee osteoarthritis taking into account both constant and intermittent pain experiences. There are two versions of this tool; one to assess pain in the knee joint and another assessing pain in the hip joint.
Baseline
Intermittent and Constant OA Pain (ICOAP)
Time Frame: 2 months
This 11-item tool is designed to assess pain in individuals with hip or knee osteoarthritis taking into account both constant and intermittent pain experiences. There are two versions of this tool; one to assess pain in the knee joint and another assessing pain in the hip joint.
2 months
Intermittent and Constant OA Pain (ICOAP)
Time Frame: 6 months
This 11-item tool is designed to assess pain in individuals with hip or knee osteoarthritis taking into account both constant and intermittent pain experiences. There are two versions of this tool; one to assess pain in the knee joint and another assessing pain in the hip joint.
6 months
Intermittent and Constant OA Pain (ICOAP)
Time Frame: 12 months
This 11-item tool is designed to assess pain in individuals with hip or knee osteoarthritis taking into account both constant and intermittent pain experiences. There are two versions of this tool; one to assess pain in the knee joint and another assessing pain in the hip joint.
12 months
Patient Global Assessment of Health Status (PGA)
Time Frame: Baseline
Patient global assessment (PGA) is one of the most widely used PROs in RA practice and research and is included in several composite scores such as the 28-joint Disease Activity Score (DAS28). PGA is often assessed by a single question with a 0-10 or 0-100 response.
Baseline
Patient Global Assessment of Health Status (PGA)
Time Frame: 2 months
Patient global assessment (PGA) is one of the most widely used PROs in RA practice and research and is included in several composite scores such as the 28-joint Disease Activity Score (DAS28). PGA is often assessed by a single question with a 0-10 or 0-100 response.
2 months
Patient Global Assessment of Health Status (PGA)
Time Frame: 6 months
Patient global assessment (PGA) is one of the most widely used PROs in RA practice and research and is included in several composite scores such as the 28-joint Disease Activity Score (DAS28). PGA is often assessed by a single question with a 0-10 or 0-100 response.
6 months
Patient Global Assessment of Health Status (PGA)
Time Frame: 12 months
Patient global assessment (PGA) is one of the most widely used PROs in RA practice and research and is included in several composite scores such as the 28-joint Disease Activity Score (DAS28). PGA is often assessed by a single question with a 0-10 or 0-100 response.
12 months
Patient Acceptable Symptom State (PASS)
Time Frame: Baseline
Patient Acceptable Symptom State (PASS) has been defined as the highest level of symptom beyond which patients consider themselves well.
Baseline
Patient Acceptable Symptom State (PASS)
Time Frame: 2 months
Patient Acceptable Symptom State (PASS) has been defined as the highest level of symptom beyond which patients consider themselves well.
2 months
Patient Acceptable Symptom State (PASS)
Time Frame: 6 months
Patient Acceptable Symptom State (PASS) has been defined as the highest level of symptom beyond which patients consider themselves well.
6 months
Patient Acceptable Symptom State (PASS)
Time Frame: 12 months
Patient Acceptable Symptom State (PASS) has been defined as the highest level of symptom beyond which patients consider themselves well.
12 months
Arthritis Self-Efficacy Questionnaire
Time Frame: Baseline
The ASES was developed to measure patients' arthritis-specific self-efficacy, or patients' beliefs that they could perform specific tasks or behaviors to cope with the consequences of arthritis.
Baseline
Arthritis Self-Efficacy Questionnaire
Time Frame: 2 months
The ASES was developed to measure patients' arthritis-specific self-efficacy, or patients' beliefs that they could perform specific tasks or behaviors to cope with the consequences of arthritis.
2 months
Arthritis Self-Efficacy Questionnaire
Time Frame: 6 months
The ASES was developed to measure patients' arthritis-specific self-efficacy, or patients' beliefs that they could perform specific tasks or behaviors to cope with the consequences of arthritis.
6 months
Arthritis Self-Efficacy Questionnaire
Time Frame: 12 months
The ASES was developed to measure patients' arthritis-specific self-efficacy, or patients' beliefs that they could perform specific tasks or behaviors to cope with the consequences of arthritis.
12 months
Center for the Epidemiological studies - Depression Scale (CES-D)
Time Frame: Baseline
The Center for Epidemiologic Studies Depression Scale is a commonly used freely available self-report measure of depressive symptoms.
Baseline
Center for the Epidemiological studies - Depression Scale (CES-D)
Time Frame: 2 months
The Center for Epidemiologic Studies Depression Scale is a commonly used freely available self-report measure of depressive symptoms.
2 months
Center for the Epidemiological studies - Depression Scale (CES-D)
Time Frame: 6 months
The Center for Epidemiologic Studies Depression Scale is a commonly used freely available self-report measure of depressive symptoms.
6 months
Center for the Epidemiological studies - Depression Scale (CES-D)
Time Frame: 12 months
The Center for Epidemiologic Studies Depression Scale is a commonly used freely available self-report measure of depressive symptoms.
12 months
Visual Analogue Scale to Evaluate Fatigue Severity (VAS-F)
Time Frame: Baseline
The scale consists of 18 items relating to the subjective experience of fatigue. Each item asks respondents to place an "X," representing how they currently feel, along a visual analogue line that extends between two extremes (e.g., from "not at all tired" to "extremely tired").
Baseline
Visual Analogue Scale to Evaluate Fatigue Severity (VAS-F)
Time Frame: 2 months
The scale consists of 18 items relating to the subjective experience of fatigue. Each item asks respondents to place an "X," representing how they currently feel, along a visual analogue line that extends between two extremes (e.g., from "not at all tired" to "extremely tired").
2 months
Visual Analogue Scale to Evaluate Fatigue Severity (VAS-F)
Time Frame: 6 months
The scale consists of 18 items relating to the subjective experience of fatigue. Each item asks respondents to place an "X," representing how they currently feel, along a visual analogue line that extends between two extremes (e.g., from "not at all tired" to "extremely tired").
6 months
Visual Analogue Scale to Evaluate Fatigue Severity (VAS-F)
Time Frame: 12 months
The scale consists of 18 items relating to the subjective experience of fatigue. Each item asks respondents to place an "X," representing how they currently feel, along a visual analogue line that extends between two extremes (e.g., from "not at all tired" to "extremely tired").
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jane Thornton, MD PhD, Western University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 18, 2021

Primary Completion (Estimated)

June 6, 2025

Study Completion (Estimated)

June 6, 2025

Study Registration Dates

First Submitted

August 24, 2020

First Submitted That Met QC Criteria

September 3, 2020

First Posted (Actual)

September 10, 2020

Study Record Updates

Last Update Posted (Actual)

June 12, 2024

Last Update Submitted That Met QC Criteria

June 10, 2024

Last Verified

June 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteoarthritis

Subscribe